Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 12-Month Low – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price hit a new 52-week low on Monday. The stock traded as low as $18.94 and last traded at $19.08, with a volume of 4,960 shares. The stock had previously closed at $19.20.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CHGCY shares. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The company has a market cap of $63.26 billion, a price-to-earnings ratio of 20.78 and a beta of 0.60. The business has a 50 day simple moving average of $20.99 and a 200 day simple moving average of $23.26.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. The company had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. As a group, sell-side analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.